– USA, FL – NAYA Biosciences (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, announced the nominations of five new candidates for its Board of Directors to be approved at the AGM on March 10th, 2025.
- Laurent Audoly, PhD:
Co-founder and CEO of PriveBio with extensive biotech experience, including leadership roles in R&D at major companies such as Pfizer and Merck. - Melissa Fensterstock, MPhil, MBA:
Former CEO and advisor who has successfully helped translate academic innovations into commercial ventures. - Prakash Raman, PhD:
CEO of InduPro, Inc., with a background in strategic development at Novartis, particularly in immuno-oncology collaborations. - Daniel Teper, PharmD, MBA:
Founder of NAYA Biosciences, bringing a diverse leadership portfolio from the pharmaceutical and digital health sectors. - Alexandra Urman, MPH:
CEO and portfolio manager with expertise in healthcare innovation, specializing in the integration of AI in biotech investments.
About NAYA Biosciences
NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and the agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics.
For more information: https://www.nayabiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.